A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
← catalyst calendarNCT06678659 · readout in 803 d
Sponsored by Recursion Pharmaceuticals Inc. (industry) · RXRX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
170estimated
Sites
6
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-21 | actual | When the study began enrolling |
| Primary completion | 2028-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Unresectable
- Locally Advanced
- Metastatic Cancers
- Relapsed/Refractory Lymphomas
Intervention
- Drug: REC-1245
Primary outcomes
what the primary-completion date above is the date OFPhase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
measured Initiation of study drug through 4 weeks
Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse Event
measured Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
Phase 2- Objective Response Rate (ORR)
measured Initiation from study drug until disease progression (up to approximately 24 months)
Permalink · RXRX's whole pipeline · Catalyst calendar · Every registered study · What changed